Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 758 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolic Syndrome x Clear all
Terminated Not applicable Interventional Results available

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

NCT00477191
View directory record Official record
Conditions
Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, Hypertension
Interventions
Etanercept
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 10, 2026, 2:34 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Noninvasive Biomarkers for Monitoring Cardiometabolic Risk in Children

NCT01465789
View directory record Official record
Conditions
Obesity, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
West Virginia School of Osteopathic Medicine
Other
Eligibility
4 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Lewisburg, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 10, 2026, 2:34 PM EDT
Completed Not applicable Interventional

Soy Nut Study on Markers of Health

NCT01173380
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Soy nuts, Matched food
Other
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 10, 2026, 2:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease

NCT07398508
View directory record Official record
Conditions
Menkes Disease
Interventions
Droxidopa Oral Product, Placebo Control
Drug · Other
Lead sponsor
Stephen G. Kaler
Other
Eligibility
7 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 10, 2026, 2:34 PM EDT
Not listed Not applicable Interventional

Cardiometabolic Syndrome Response to Therapeutic Lifestyle Changes

NCT04093440
View directory record Official record
Conditions
Metabolic Syndrome, ASCVD, Lifestyle Risk Reduction
Interventions
lifestyle modification
Other
Lead sponsor
Holy Cross Hospital, Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 10, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

NCT04977388
View directory record Official record
Conditions
Menkes Disease, Occipital Horn Syndrome
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Stephen G. Kaler, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 10, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Metabolic Syndrome and Insulin Resistance at Allina

NCT01545830
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
vitamin D3 (cholecalciferol)
Dietary Supplement
Lead sponsor
Allina Health System
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 10, 2026, 2:34 PM EDT
Completed Phase 4 Interventional Results available

Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

NCT02034435
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Low Salt diet plus Placebo tablet, Low Sodium diet plus Salt tablet, Epleronone, Amlodipine
Other · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 10, 2026, 2:34 PM EDT
Completed No phase listed Observational

Evaluation of Intra-Abdominal Fat in Patients With Type 2 Diabetes Using a Non-Invasive Method

NCT01283113
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 10, 2026, 2:34 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

NCT05371613
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
tividenofusp alfa, idursulfase
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Oakland, California • Chicago, Illinois • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 10, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Bone Marrow Transplant With Abatacept for Non-Malignant Diseases

NCT01917708
View directory record Official record
Conditions
Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Shwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia, Thalassemia Major, Hemophagocytic Lymphohistiocytosis, Sickle Cell Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 10, 2026, 2:34 PM EDT
Completed Not applicable Interventional

The Impact of Time Restricted Feeding (TRF) in Improving the Health of Patients With Metabolic Syndrome

NCT03182985
View directory record Official record
Conditions
Weight Loss, Metabolic Syndrome, Overweight and Obesity
Interventions
Time Restricted Feeding
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 10, 2026, 2:34 PM EDT
Completed No phase listed Observational

Association of Genes to Resistance to Weight Loss in Obese Patients

NCT00858221
View directory record Official record
Conditions
Obesity, Metabolic Syndrome, Dyslipidemia
Interventions
Not listed
Lead sponsor
Interleukin Genetics, Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
824 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2009 · Synced Oct 10, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)

NCT01244503
View directory record Official record
Conditions
Metabolic Syndrome, Nonalcoholic Fatty Liver Disease
Interventions
Sodium Octanoate Breath Test
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Oct 10, 2026, 2:34 PM EDT
Completed No phase listed Observational

The SEEA (SCI Energy Expenditure and Activity) Study

NCT04748835
View directory record Official record
Conditions
Spinal Cord Injuries, Obesity, Metabolic Syndrome, Cardiovascular Diseases, Diet Habit
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 10, 2026, 2:34 PM EDT
Completed No phase listed Observational

Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles

NCT00086476
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 10, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Interventional Bioremediation of Microbiota in Metabolic Syndrome

NCT02730962
View directory record Official record
Conditions
Pre-Diabetes
Interventions
Vancomycin, Placebo, Neomycin, Clindamycin, Fecal Microbiota Transplantation
Drug · Other · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 10, 2026, 2:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome

NCT03098797
View directory record Official record
Conditions
Barth Syndrome
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 10, 2026, 2:34 PM EDT
Completed Not applicable Interventional Results available

Lifestyle Modification and Metformin Use in the Treatment of HIV

NCT00399360
View directory record Official record
Conditions
HIV Infections, Metabolic Syndrome X
Interventions
Metformin, Placebo, Lifestyle Modification
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 10, 2026, 2:34 PM EDT
Completed No phase listed Observational

Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID

NCT00006335
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
13 Years to 17 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 10, 2026, 2:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Metabolic Syndrome Study

NCT03570840
View directory record Official record
Conditions
Metabolic Syndrome, Overweight and Obesity, Cardiovascular Risk Factor
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
4 Years to 21 Years
Enrollment
477 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 10, 2026, 2:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II

NCT00799643
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Salsalate, Salsalate Placebo
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
21
States / cities
Birmingham, Alabama • San Diego, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 10, 2026, 2:34 PM EDT
Completed Phase 2 Interventional

A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism

NCT00327002
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
LY518674
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 10, 2026, 2:34 PM EDT
Completed Not applicable Interventional Results available

Reducing Metabolic Syndrome Among Breast Cancer Survivors

NCT03719677
View directory record Official record
Conditions
Breast Cancer
Interventions
Habit development intervention
Behavioral
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
40 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 10, 2026, 2:34 PM EDT